The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Nucleic Acid-based Drugs-Global Market Insights and Sales Trends 2025
Synopsis
The global Nucleic Acid-based Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Nucleic Acid-based Drugs in various end use industries. The expanding demands from the Genetic Disease, Cancer, Cardiovascular Diseases and Other, are propelling Nucleic Acid-based Drugs market. ASO, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the mRNA segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Nucleic Acid-based Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Nucleic Acid-based Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Nucleic Acid-based Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Nucleic Acid-based Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Nucleic Acid-based Drugs covered in this report include Ionis Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku, BioNTech, Moderna Therapeutics, CureVac, Alnylam Pharmaceuticals, Regulus Therapeutics and Miragen Therapeutics, etc.
The global Nucleic Acid-based Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
BioNTech
Moderna Therapeutics
CureVac
Alnylam Pharmaceuticals
Regulus Therapeutics
Miragen Therapeutics
Mina Therapeutics
NeXstar Pharmaceuticals
Global Nucleic Acid-based Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Nucleic Acid-based Drugs market, Segment by Type:
ASO
mRNA
siRNA
miRNA
saRNA
Aptamer
Global Nucleic Acid-based Drugs market, by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Nucleic Acid-based Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Nucleic Acid-based Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Nucleic Acid-based Drugs in various end use industries. The expanding demands from the Genetic Disease, Cancer, Cardiovascular Diseases and Other, are propelling Nucleic Acid-based Drugs market. ASO, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the mRNA segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Nucleic Acid-based Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Nucleic Acid-based Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Nucleic Acid-based Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Nucleic Acid-based Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Nucleic Acid-based Drugs covered in this report include Ionis Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku, BioNTech, Moderna Therapeutics, CureVac, Alnylam Pharmaceuticals, Regulus Therapeutics and Miragen Therapeutics, etc.
The global Nucleic Acid-based Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
BioNTech
Moderna Therapeutics
CureVac
Alnylam Pharmaceuticals
Regulus Therapeutics
Miragen Therapeutics
Mina Therapeutics
NeXstar Pharmaceuticals
Global Nucleic Acid-based Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Nucleic Acid-based Drugs market, Segment by Type:
ASO
mRNA
siRNA
miRNA
saRNA
Aptamer
Global Nucleic Acid-based Drugs market, by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Nucleic Acid-based Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Nucleic Acid-based Drugs
1.1 Nucleic Acid-based Drugs Market Overview
1.1.1 Nucleic Acid-based Drugs Product Scope
1.1.2 Nucleic Acid-based Drugs Market Status and Outlook
1.2 Global Nucleic Acid-based Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Nucleic Acid-based Drugs Market Size by Region (2018-2029)
1.4 Global Nucleic Acid-based Drugs Historic Market Size by Region (2018-2023)
1.5 Global Nucleic Acid-based Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Nucleic Acid-based Drugs Market Size (2018-2029)
1.6.1 North America Nucleic Acid-based Drugs Market Size (2018-2029)
1.6.2 Europe Nucleic Acid-based Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Nucleic Acid-based Drugs Market Size (2018-2029)
1.6.4 Latin America Nucleic Acid-based Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Nucleic Acid-based Drugs Market Size (2018-2029)
2 Nucleic Acid-based Drugs Market by Type
2.1 Introduction
2.1.1 ASO
2.1.2 mRNA
2.1.3 siRNA
2.1.4 miRNA
2.1.5 saRNA
2.1.6 Aptamer
2.2 Global Nucleic Acid-based Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Nucleic Acid-based Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Nucleic Acid-based Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Nucleic Acid-based Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Nucleic Acid-based Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Nucleic Acid-based Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Nucleic Acid-based Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Nucleic Acid-based Drugs Revenue Breakdown by Type (2018-2029)
3 Nucleic Acid-based Drugs Market Overview by Application
3.1 Introduction
3.1.1 Genetic Disease
3.1.2 Cancer
3.1.3 Cardiovascular Diseases
3.1.4 Other
3.2 Global Nucleic Acid-based Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Nucleic Acid-based Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Nucleic Acid-based Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Nucleic Acid-based Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Nucleic Acid-based Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Nucleic Acid-based Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Nucleic Acid-based Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Nucleic Acid-based Drugs Revenue Breakdown by Application (2018-2029)
4 Nucleic Acid-based Drugs Competition Analysis by Players
4.1 Global Nucleic Acid-based Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Nucleic Acid-based Drugs as of 2022)
4.3 Date of Key Players Enter into Nucleic Acid-based Drugs Market
4.4 Global Top Players Nucleic Acid-based Drugs Headquarters and Area Served
4.5 Key Players Nucleic Acid-based Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Nucleic Acid-based Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Ionis Pharmaceuticals
5.1.1 Ionis Pharmaceuticals Profile
5.1.2 Ionis Pharmaceuticals Main Business
5.1.3 Ionis Pharmaceuticals Nucleic Acid-based Drugs Products, Services and Solutions
5.1.4 Ionis Pharmaceuticals Nucleic Acid-based Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Ionis Pharmaceuticals Recent Developments
5.2 Sarepta Therapeutics
5.2.1 Sarepta Therapeutics Profile
5.2.2 Sarepta Therapeutics Main Business
5.2.3 Sarepta Therapeutics Nucleic Acid-based Drugs Products, Services and Solutions
5.2.4 Sarepta Therapeutics Nucleic Acid-based Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Sarepta Therapeutics Recent Developments
5.3 Nippon Shinyaku
5.3.1 Nippon Shinyaku Profile
5.3.2 Nippon Shinyaku Main Business
5.3.3 Nippon Shinyaku Nucleic Acid-based Drugs Products, Services and Solutions
5.3.4 Nippon Shinyaku Nucleic Acid-based Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 BioNTech Recent Developments
5.4 BioNTech
5.4.1 BioNTech Profile
5.4.2 BioNTech Main Business
5.4.3 BioNTech Nucleic Acid-based Drugs Products, Services and Solutions
5.4.4 BioNTech Nucleic Acid-based Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 BioNTech Recent Developments
5.5 Moderna Therapeutics
5.5.1 Moderna Therapeutics Profile
5.5.2 Moderna Therapeutics Main Business
5.5.3 Moderna Therapeutics Nucleic Acid-based Drugs Products, Services and Solutions
5.5.4 Moderna Therapeutics Nucleic Acid-based Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Moderna Therapeutics Recent Developments
5.6 CureVac
5.6.1 CureVac Profile
5.6.2 CureVac Main Business
5.6.3 CureVac Nucleic Acid-based Drugs Products, Services and Solutions
5.6.4 CureVac Nucleic Acid-based Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 CureVac Recent Developments
5.7 Alnylam Pharmaceuticals
5.7.1 Alnylam Pharmaceuticals Profile
5.7.2 Alnylam Pharmaceuticals Main Business
5.7.3 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Products, Services and Solutions
5.7.4 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Alnylam Pharmaceuticals Recent Developments
5.8 Regulus Therapeutics
5.8.1 Regulus Therapeutics Profile
5.8.2 Regulus Therapeutics Main Business
5.8.3 Regulus Therapeutics Nucleic Acid-based Drugs Products, Services and Solutions
5.8.4 Regulus Therapeutics Nucleic Acid-based Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Regulus Therapeutics Recent Developments
5.9 Miragen Therapeutics
5.9.1 Miragen Therapeutics Profile
5.9.2 Miragen Therapeutics Main Business
5.9.3 Miragen Therapeutics Nucleic Acid-based Drugs Products, Services and Solutions
5.9.4 Miragen Therapeutics Nucleic Acid-based Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Miragen Therapeutics Recent Developments
5.10 Mina Therapeutics
5.10.1 Mina Therapeutics Profile
5.10.2 Mina Therapeutics Main Business
5.10.3 Mina Therapeutics Nucleic Acid-based Drugs Products, Services and Solutions
5.10.4 Mina Therapeutics Nucleic Acid-based Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Mina Therapeutics Recent Developments
5.11 NeXstar Pharmaceuticals
5.11.1 NeXstar Pharmaceuticals Profile
5.11.2 NeXstar Pharmaceuticals Main Business
5.11.3 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Products, Services and Solutions
5.11.4 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 NeXstar Pharmaceuticals Recent Developments
6 North America
6.1 North America Nucleic Acid-based Drugs Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Nucleic Acid-based Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Nucleic Acid-based Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Nucleic Acid-based Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Nucleic Acid-based Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Nucleic Acid-based Drugs Market Dynamics
11.1 Nucleic Acid-based Drugs Industry Trends
11.2 Nucleic Acid-based Drugs Market Drivers
11.3 Nucleic Acid-based Drugs Market Challenges
11.4 Nucleic Acid-based Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
